76635-31-9

Usage

Uses

Used in Pharmaceutical Synthesis:
4-(3-methyl-1,2,4-oxadiazol-5-yl)aniline is used as a key intermediate in the synthesis of pharmaceuticals for its ability to contribute to the development of new medicinal compounds with diverse therapeutic properties.
Used in Agrochemical Development:
In the agrochemical industry, 4-(3-methyl-1,2,4-oxadiazol-5-yl)aniline is utilized as a precursor in the creation of agrochemicals, potentially leading to the discovery of new pesticides or other agricultural chemicals that can enhance crop protection and yield.
Safety Considerations:
Given its chemical reactivity and potential health risks, researchers and handlers of 4-(3-methyl-1,2,4-oxadiazol-5-yl)aniline must exercise caution and adhere to safety protocols to mitigate any hazards associated with its use.

InChI:InChI=1/C9H9N3O/c1-6-11-9(13-12-6)7-2-4-8(10)5-3-7/h2-5H,10H2,1H3

Upstream product

• 1455-82-9 3-methyl-5-(4'-nitrophenyl)-1,2,4-oxadiazole 
• 122-04-3 4-nitro-benzoyl chloride 

Downstream Products

• 1255700-20-9 4-methyl-8-(4-(3-methyl-1,2,4-oxadiazol-5-yl)phenylamino)-2-phenyl-3,4-dihydropyrido[3,2-f][1,4]oxazepin-5(2H)-one 

Relevant academic research and scientific papers

Discovery of a Potent Glutathione Peroxidase 4 Inhibitor as a Selective Ferroptosis Inducer

Potent and selective ferroptosis regulators promote an intensive understanding of the regulation and mechanisms underlying ferroptosis, which is highly associated with various diseases. In this study, through a stepwise structure optimization, a potent and selective ferroptosis inducer was developed targeting to inhibit glutathione peroxidase 4 (GPX4), and the structure-activity relationship (SAR) of these compounds was uncovered. Compound26aexhibited outstanding GPX4 inhibitory activity with a percent inhibition up to 71.7% at 1.0 μM compared to 45.9% of RSL-3. At the cellular level,26acould significantly induce lipid peroxide (LPO) increase and effectively induce ferroptosis with satisfactory selectivity (the value of 31.5). The morphological analysis confirmed the ferroptosis induced by26a. Furthermore,26asignificantly restrained tumor growth in a mouse 4T1 xenograft model without obvious toxicity.

1-(CYCLOALKYL-CARBONYL)PROLINE DERIVATIVE

A compound represented by formula (1) (in the formula: ring-D represents a three- to eight-membered hydrocarbon ring; Ra represents an optionally substituted amino C1-6 alkyl group or the like; Rb1 and Rb2 each independently represent a hydrogen atom, a halogen atom, or the like; Rc represents an optionally substituted C6-10 aryl group or the like; Rd represents a hydrogen atom or the like; and ring-Q represents a (hetero)aryl group or the like which may be substituted with a carboxyl group or the like) or a pharmaceutically acceptable salt thereof exhibits an excellent FXIa inhibitory activity, and is useful as a therapeutic agent against thrombosis or the like.

Synthesis and methemoglobinemia-inducing properties of benzocaine isosteres designed as humane rodenticides

A number of isosteres (oxadiazoles, thiadiazoles, tetrazoles and diazines) of benzocaine were prepared and evaluated for their capacity to induce methemoglobinemia - with a view to their possible application as humane pest control agents. It was found that an optimal lipophilicity for the formation of methemoglobin (metHb) in vitro existed within each series, with 1,2,4-oxadiazole 3 (metHb% = 61.0 ± 3.6) and 1,3,4-oxadiazole 10 (metHb% = 52.4 ± 0.9) demonstrating the greatest activity. Of the 5 candidates (compounds 3, 10, 11, 13 and 23) evaluated in vivo, failure to induce a lethal end-point at doses of 120 mg/kg was observed in all cases. Inadequate metabolic stability, particularly towards hepatic enzymes such as the CYPs, was postulated as one reason for their failure.

Muscarinic acetylcholine receptor antagonists: SAR and optimization of tyrosine ureas

SAR exploration of multiple regions of a tyrosine urea template led to the identification of very potent muscarinic acetylcholine receptor antagonists such as 10b with good subtype selectivity for M3 over M1. The structure-activity r

CHROMAN COMPOUNDS AS 5 -HTlB ANTAGONISTS

Chroman derivatives according to Formula (I) below: wherein R1, R2, R3 ,and R4 are as defined in the specification, pharmaceutically-acceptable salts, methods of making, pharmaceutical .compositions containing a

Selective Reduction of Nitro-Heterocycles with Sodium Sulfide in Aqueous p-Dioxane

Nitro-heterocycles, particularly those containing halogen, were selectively reduced with sodium sulfide in aqueous p-dioxane to give the corresponding amino-heterocycles in 70-89percent yields.